TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31583977

Group type: EXPERIMENTAL
Intervention: Relaxation video intervention
Number of subjects: 30

Group type: COMPARATOR
Intervention: Discussion about disease (Control)
Number of subjects: 30
Study: 29480916

Group type: EXPERIMENTAL
Intervention: Osteopathic Manipulative Treatment (OMT) for a maximum of 20 minutes
Number of subjects: 60

Group type: COMPARATOR
Intervention: Seated Control (waiting for 30 minutes)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Walking Control (walking for 5 minutes)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All groups (OMT, seated control, walking control)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Palpatory assessment of SBP and SSD
Number of subjects: 60
Study: 29141653

Group type: EXPERIMENTAL
Intervention: Prescriber Recruitment Bundle (PRB) intervention implemented over a 24-month period with a 10-month sustainability period.
Number of subjects: 70

Group type: COMPARATOR
Intervention: Treatment as usual with access to a website with PRB resources.
Number of subjects: 70
Study: 26090709

Group type: EXPERIMENTAL
Intervention: Classic rollerskiing technique
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Skate rollerskiing technique
Number of subjects: 7

Group type: COMPARATOR
Intervention: Both techniques (classic and skate)
Number of subjects: 7
Study: 23168372

Group type: EXPERIMENTAL
Intervention: BFR-RE
Number of subjects: 27

Group type: COMPARATOR
Intervention: RE
Number of subjects: 27
Study: 21102387

Group type: EXPERIMENTAL
Intervention: Sevoflurane-based inhalational anesthesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intravenous anesthesia with propofol
Number of subjects: 30
Study: 19378515

Group type: EXPERIMENTAL
Intervention: 0.3 mg kg(‐1) of rocuronium (1 ED95)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.6 mg kg(‐1) of rocuronium (2 ED95)
Number of subjects: 60
Study: 15901044

Group type: EXPERIMENTAL
Intervention: Test formulation (25 mg carvedilol tablets)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Reference formulation (25 mg carvedilol tablets)
Number of subjects: 24
Study: 14642046

Group type: EXPERIMENTAL
Intervention: Transurethral rotoresection (TURotor; N = 58)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Standard transurethral resection of the prostate (TURP; N = 70)
Number of subjects: 128
Study: 11107080

Group type: EXPERIMENTAL
Intervention: Elective AAA repair (eAAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ruptured AAA repair (rAAA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictors of death from eAAA
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Predictors of death from rAAA
Number of subjects: 0
Study: 8799402

Group type: EXPERIMENTAL
Intervention: OKY 046 (0.2 mg/kg/hr)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (no drug given)
Number of subjects: 22
Study: 1623908

Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms orally + placebo i.v.
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Clonidine 200 micrograms orally + naloxone i.v. (2.8 mg/5 h)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (placebo i.v.)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (naloxone i.v.)
Number of subjects: 10
Study: 6386002

Group type: EXPERIMENTAL
Intervention: Dipyridamole (225 mg/day) and Aspirin (975 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Dipyridamole and Aspirin
Number of subjects: 28
Study: 30976908

Group type: EXPERIMENTAL
Intervention: Fixed dosing of palonosetron (0.075 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Body size‐based dosing of palonosetron
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: LBW-based dosing of palonosetron
Number of subjects: 51
Study: 30410128

Group type: EXPERIMENTAL
Intervention: Intralesional triamcinolone injection followed by dilatation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Dilatation alone
Number of subjects: 60
Study: 27869358

Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1379

Group type: COMPARATOR
Intervention: Washout
Number of subjects: 1379
Study: 23434617

Group type: EXPERIMENTAL
Intervention: High ligation and stripping (HL&S)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation with ClosureFast (RFA)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Endovenous laser ablation (EVLA)
Number of subjects: 45
Study: 22971669

Group type: EXPERIMENTAL
Intervention: Duloxetine 30 mg/d
Number of subjects: 308

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 308
Study: 19428118

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 223
Study: 18841533

Group type: EXPERIMENTAL
Intervention: Cue-based feeding (intervention group)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Traditional feeding regimen (control group)
Number of subjects: 79
Study: 16970087

Group type: EXPERIMENTAL
Intervention: Yanshu Injection (20 ml daily)
Number of subjects: 150
Study: 12814448

Group type: EXPERIMENTAL
Intervention: Levosimendan administered by intravenous infusion
Number of subjects: 190
Study: 11227684

Group type: EXPERIMENTAL
Intervention: Music therapy intervention during the first dressing change (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: No music therapy intervention during the first dressing change (Group B)
Number of subjects: 25
Study: 9140019

Group type: COMPARATOR
Intervention: Melatonin (5 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: S-20098 (5 mg and 100 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 7956632

Group type: EXPERIMENTAL
Intervention: DQB1*0201 and DQB1*0302 alleles
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DQB1*0301 and DQB1*0601 alleles
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Homozygous non‐aspartic acid residue (NA/NA) at position 57
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Homozygous aspartic acid (A/A) at position 57
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: DQB1*0201/DQB1*0303 genotype among NA/A heterozygotes
Number of subjects: 48
Study: 3654132

Group type: EXPERIMENTAL
Intervention: 3 mL antiseptic soap
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1 mL antiseptic soap
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control liquid soap
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: General population and nursing staff
Number of subjects: 40
Study: 30805607

Group type: EXPERIMENTAL
Intervention: Energy Drink (ED)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Product (CP)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control Product (CP) supplemented with ED-ingredients
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: All study products
Number of subjects: 38
Study: 28284187

Group type: EXPERIMENTAL
Intervention: RISKIT-CJS intervention in addition to treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual alone
Number of subjects: 0
Study: 25218352

Group type: EXPERIMENTAL
Intervention: TIPU repair with dorsal dartos flap
Number of subjects: 214

Group type: COMPARATOR
Intervention: Flapless TIPU repair
Number of subjects: 214
Study: 23958469

Group type: EXPERIMENTAL
Intervention: Theory-informed implementation intervention (interactive, opinion leader-led, educational face-to-face workshop)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Printed copy of the guideline (control group)
Number of subjects: 60
Study: 21848415

Group type: EXPERIMENTAL
Intervention: Pulsing electromagnetic generator
Number of subjects: 117
Study: 19390517

Group type: EXPERIMENTAL
Intervention: Diet (D group; n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Diet + Exercise (D+E group; n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Control (D group)
Number of subjects: 18
Study: 16396771

Group type: EXPERIMENTAL
Intervention: ViGePP regimen (gemcitabine, vinorelbine, procarbazine, and prednisone) administered every 4 weeks up to six courses.
Number of subjects: 69
Study: 15282264

Group type: EXPERIMENTAL
Intervention: Estropipate (an estrogen substitute)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 11531149

Group type: EXPERIMENTAL
Intervention: Insulin-meal interval of 15 min
Number of subjects: 11

Group type: COMPARATOR
Intervention: Insulin-meal interval of 30 min
Number of subjects: 11
Study: 9280186

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (30 mg/d as amino acid chelate for 3 weeks)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 20
Study: 8285322

Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 47
Study: 30452427

Group type: EXPERIMENTAL
Intervention: PD training using a PD simulator
Number of subjects: 28

Group type: COMPARATOR
Intervention: Videos for PD training (Control)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Experimental group (PD simulator)
Number of subjects: 28
Study: 29735880

Group type: EXPERIMENTAL
Intervention: Neurofeedback training (10 sessions, 30 minutes each, involving high-beta, theta, and sensory motor rhythm training)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Neurofeedback training
Number of subjects: 78
Study: 27009070

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (T0)
Number of subjects: 26231

Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (T1)
Number of subjects: 26231
Study: 25042307

Group type: EXPERIMENTAL
Intervention: Exercise Group (EG)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 42
Study: 22108915

Group type: EXPERIMENTAL
Intervention: 2 mg oral estradiol (n=6)
Number of subjects: 11

Group type: COMPARATOR
Intervention: 50 μg/day transdermal 17β‐estradiol (n=5)
Number of subjects: 11
Study: 20404290

Group type: EXPERIMENTAL
Intervention: Consultation group (n = 30) received a tape of their consultation interview
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Generic group (n = 25) received a tape about coronary artery surgery
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control group (n = 29) received no tape
Number of subjects: 84
Study: 18028044

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS) (40 microg fentanyl/dose)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA) (1 mg morphine/dose)
Number of subjects: 506

Group type: EXPERIMENTAL
Intervention: Fentanyl iontophoretic transdermal system (ITS)
Number of subjects: 506

Group type: COMPARATOR
Intervention: Morphine intravenous patient-controlled analgesia (IV PCA)
Number of subjects: 506
Study: 15704203

Group type: EXPERIMENTAL
Intervention: Denufosol (10, 20, 40, and 60 mg, administered by inhalation via the Pari LC Star nebulizer)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Denufosol (maximum tolerated dose)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Denufosol and Placebo
Number of subjects: 61
Study: 12013151

Group type: EXPERIMENTAL
Intervention: Chondroitin sulfate 800 mg/day plus naproxen 500 mg/day
Number of subjects: 24

Group type: COMPARATOR
Intervention: Naproxen 500 mg/day
Number of subjects: 24
Study: 9925227

Group type: EXPERIMENTAL
Intervention: Computer-based histology atlas
Number of subjects: 0

Group type: COMPARATOR
Intervention: No computer-based histology atlas (control group)
Number of subjects: 0
Study: 7588504

Group type: EXPERIMENTAL
Intervention: High-amylose corn starch (RS2)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extruded and retrograded high-amylose corn starch (RS3)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: RS2
Number of subjects: 24
Study: 1702916

Group type: EXPERIMENTAL
Intervention: Pygeum africanum extract (50 mg capsules, 1 capsule in the morning and 1 capsule in the evening for 60 days)
Number of subjects: 263

Group type: COMPARATOR
Intervention: Placebo (1 capsule in the morning and 1 capsule in the evening for 60 days)
Number of subjects: 263
Study: 531221

Group type: EXPERIMENTAL
Intervention: 3000 microgram (155)-methyl PGF2 alpha methyl ester (U-36,384) via slow release vaginal suppository
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 500 microgram 16-phenoxy-omega-tetranor PGE2 methyl sulfonylamide (Sulproston) via intramuscular injection at 4 hour intervals, totaling 1250 +/- 154 microgram
Number of subjects: 20
Study: 31478764

Group type: EXPERIMENTAL
Intervention: Bone fixed group (with PSIS fixed DRF)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Skin fixed group (with cutaneously fixed DRF)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Skin fixed DRF
Number of subjects: 100
Study: 29405667

Group type: EXPERIMENTAL
Intervention: Sugammadex 2 mg/kg
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neostigmine 50 µg/kg
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 55

Group type: COMPARATOR
Intervention: Neostigmine
Number of subjects: 55
Study: 26844419

Group type: EXPERIMENTAL
Intervention: Active tDCS of the motor cortex
Number of subjects: 30

Group type: COMPARATOR
Intervention: Sham (placebo) tDCS
Number of subjects: 30
Study: 24718736

Group type: EXPERIMENTAL
Intervention: Knee flexion at 90° for the first 6 hours after surgery
Number of subjects: 100

Group type: COMPARATOR
Intervention: Knee extension for the first 6 hours after surgery (Control)
Number of subjects: 100
Study: 22244638

Group type: EXPERIMENTAL
Intervention: Self‐Adjusting File (SAF)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ProTaper file system
Number of subjects: 20
Study: 19878447

Group type: EXPERIMENTAL
Intervention: Dapoxetine 30 mg
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Dapoxetine 60 mg
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1067
Study: 17709859

Group type: EXPERIMENTAL
Intervention: Cervical pedicle screw fixation feasibility
Number of subjects: 80
Study: 15814549

Group type: EXPERIMENTAL
Intervention: tacrolimus and MMF
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: cyclosporin ME and MMF
Number of subjects: 205

Group type: COMPARATOR
Intervention: corticosteroid therapy
Number of subjects: 205
Study: 12488788

Group type: EXPERIMENTAL
Intervention: Alzheimer patients
Number of subjects: 20

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 20
Study: 9813557

Group type: EXPERIMENTAL
Intervention: Losartan (30 micrograms/min)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Losartan (90 micrograms/min)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Lower body negative pressure
Number of subjects: 9
Study: 7709947

Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide)
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter)
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide) in women not receiving antibiotics
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter) in women not receiving antibiotics
Number of subjects: 1309

Group type: EXPERIMENTAL
Intervention: Silver-coated catheter (5% silver oxide) in men not receiving antibiotics
Number of subjects: 1309

Group type: COMPARATOR
Intervention: Control group (standard silicone elastomer-coated latex catheter) in men not receiving antibiotics
Number of subjects: 1309
Study: 2704247

Group type: EXPERIMENTAL
Intervention: Apomorphine (0.009 mg/kg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 342185

Group type: EXPERIMENTAL
Intervention: Chlorpromazine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 30338354

Group type: EXPERIMENTAL
Intervention: Peer support via telephone (1 to 5 times according to preference)
Number of subjects: 260

Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 260
Study: 29527812

Group type: EXPERIMENTAL
Intervention: Closed-incision negative pressure therapy (ciNPT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Control group with conventional dressing
Number of subjects: 132
Study: 26945586

Group type: COMPARATOR
Intervention: COMPASS program (multi-component curriculum-based safe spaces program)
Number of subjects: 1805

Group type: COMPARATOR
Intervention: COMPASS program (including caregiver component)
Number of subjects: 1805

Group type: COMPARATOR
Intervention: COMPASS program
Number of subjects: 1805
Study: 24934734

Group type: EXPERIMENTAL
Intervention: Percutaneous aspiration thrombectomy (PAT) followed by standard anticoagulant therapy
Number of subjects: 42

Group type: COMPARATOR
Intervention: Anticoagulation therapy alone
Number of subjects: 42
Study: 22317489

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study: 21413416

Group type: EXPERIMENTAL
Intervention: Midazolam (7.5‐15 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Clonidine (150 mg)
Number of subjects: 60
Study: 17328989

Group type: EXPERIMENTAL
Intervention: Thalidomide 200 mg daily as maintenance therapy
Number of subjects: 30
Study: 16534857

Group type: EXPERIMENTAL
Intervention: Naltrexone
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 12612903

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b (3 MU 3 times a week) plus 1000‐1200 mg/day ribavirin for 1 year
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Interferon alfa‐2b plus ribavirin
Number of subjects: 52
Study: 10234597

Group type: EXPERIMENTAL
Intervention: Montelukast 10 mg daily by mouth
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 10159739

Group type: EXPERIMENTAL
Intervention: Intubation in the ambulance
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intubation in the rescue squad station
Number of subjects: 20
Study: 1677267

Group type: EXPERIMENTAL
Intervention: Topical bunazosin 0.3%
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 6658949

Group type: EXPERIMENTAL
Intervention: Anticoagulant (AC)
Number of subjects: 241

Group type: COMPARATOR
Intervention: Acetylsalicylic acid (ASA)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Both AC and ASA
Number of subjects: 241
Study: 31775685

Group type: EXPERIMENTAL
Intervention: Guided Internet-based self-help Problem Solving Therapy (PST) for 5 weeks
Number of subjects: 206

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Guided Internet-based self-help Problem Solving Therapy (PST)
Number of subjects: 206
Study: 28427734

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Heparin and glycoprotein IIb/IIIa inhibitor
Number of subjects: 3602

Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 3602
Study: 26168496

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin (PLD) 30 mg/m² and irinotecan (CPT‐11) 50 mg/m²
Number of subjects: 6
Study: 23425430

Group type: EXPERIMENTAL
Intervention: Fixed-combination brinzolamide 1%/brimonidine 0.2% (BBFC)
Number of subjects: 690

Group type: COMPARATOR
Intervention: Brinzolamide 1%
Number of subjects: 690

Group type: COMPARATOR
Intervention: Brimonidine 0.2%
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 690
Study: 21271174

Group type: EXPERIMENTAL
Intervention: Sufentanil (0.1 µg/kg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Clonidine (0.5 µg/kg)
Number of subjects: 60
Study: 19553878

Group type: EXPERIMENTAL
Intervention: Psychological treatments
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Algorithm-based care (psychological and psychopharmacological approaches)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible combination of antidepressants and psychotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: No single treatment identified
Number of subjects: 0
Study: 17526548

Group type: EXPERIMENTAL
Intervention: Clinical decision support system (CDSS) for managing renal anaemia, including treatment algorithms for Epoetin doses and iron supplements.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical measures of haemodialysis (HD) and peritoneal dialysis (PD).
Number of subjects: 0
Study: 15213038

Group type: EXPERIMENTAL
Intervention: Weight loss group with high calcium intake (HiCa: 1.8 g/d)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Weight loss group with normal calcium intake (NlCa: 1 g/d)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Weight maintenance group (WM)
Number of subjects: 73
Study: 12362493

Group type: EXPERIMENTAL
Intervention: Episiotomy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Routine episiotomy
Number of subjects: 0
Study: 9671875

Group type: EXPERIMENTAL
Intervention: Goserelin plus antiandrogen therapy
Number of subjects: 813

Group type: COMPARATOR
Intervention: Leuprolide plus antiandrogen therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Leuprolide plus flutamide therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Goserelin plus bicalutamide therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Goserelin plus flutamide therapy
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Leuprolide plus bicalutamide therapy
Number of subjects: 813
Study: 8044010

Group type: EXPERIMENTAL
Intervention: Xijian Tongshuan pill (XJTS)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Dextranum and Venoruton (Control group A)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Cyclandelate capsule (Control group B)
Number of subjects: 70
Study: 2585558

Group type: EXPERIMENTAL
Intervention: Esophageal tracheal Combitube (ETC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Endotracheal airway (ETA)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Mask ventilation
Number of subjects: 12